Treatment of Adult-Onset Immunodeficiency With Bortezomib

Summary

This is pilot study aimed to investigate the application of proteosome inhibitor, Bortezomib in treatment of patients with neutralizing autoantibody to IFN-γ. The investigators hypothesis is that bortezomib will reduce the antibody level and restore interferon-gamma function, resulting in clinical improvement and should be well-tolerated and safe for use in patients with autoantibody to IFN-γ.

Timeline

Start

2017-02-27

Primary completion

2018-11-01

Completion

2019-11-01

Outcome

Missed primary endpoint

paper Treatment with BTZ followed by cyclophosphamide yielded no significant decrease in antibody titer levels PMID 37947190 ↗

Publications

• Angkasekwinai N, Suputtamongkol Y, Tantibhedhyangkul W, Onlamoon N, Phoompoung P, Pithukpakorn M, Karuphong E, Pusuwan P, Angkasekwinai P. Efficacy of Bortezomib for Treating Anti-Interferon-Gamma Autoantibody-Associated Adult-Onset Immunodeficiency Syndrome. Clin Infect Dis. 2024 Apr 10;78(4):1033-1042. doi: 10.1093/cid/ciad676.

Drugs

Indications